ECSP13012712A - Mutantes fc de anticuerpos resistentes a proteasas activas - Google Patents

Mutantes fc de anticuerpos resistentes a proteasas activas

Info

Publication number
ECSP13012712A
ECSP13012712A ECSP13012712A ECSP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A
Authority
EC
Ecuador
Prior art keywords
mutants
active proteases
containing molecules
antibodies resistant
antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
William Strohl
Randall Brezski
Robert Jordan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP13012712A publication Critical patent/ECSP13012712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El anticuerpo monoclonal y otras moléculas que contienen Fc se pueden construir por medio del uso de las variaciones descritas en la región Fc que provocan un aumento de la resistencia a las proteasas derivadas de los huéspedes y patógenos y exhiben la capacidad para interactuar con los receptores Fc? e iniciar la citotoxicidad dirigida por el complemento como se demostró por los ensayos funcionales. Las moléculas que contienen Fc son útiles en el tratamiento de diversas enfermedades y trastornos, en donde las funciones del huésped impulsadas por el FcR aportan la actividad.
ECSP13012712 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas ECSP13012712A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US201161540882P 2011-09-29 2011-09-29
PCT/US2011/065174 WO2012087746A1 (en) 2010-12-23 2011-12-15 Active protease-resistant antibody fc mutants
US13/555,334 US8871204B2 (en) 2010-12-23 2012-07-23 Active protease-resistant antibody FC mutants

Publications (1)

Publication Number Publication Date
ECSP13012712A true ECSP13012712A (es) 2013-08-30

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012712 ECSP13012712A (es) 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas

Country Status (33)

Country Link
US (2) US8871204B2 (es)
EP (1) EP2654780B1 (es)
JP (1) JP6012624B2 (es)
KR (1) KR101900280B1 (es)
CN (1) CN103260640B (es)
AU (1) AU2011349719B2 (es)
BR (1) BR112013018317A2 (es)
CA (1) CA2822366A1 (es)
CO (1) CO6741179A2 (es)
CR (1) CR20130292A (es)
CY (1) CY1118923T1 (es)
DK (1) DK2654780T3 (es)
EA (1) EA028658B1 (es)
EC (1) ECSP13012712A (es)
ES (1) ES2623912T3 (es)
GT (1) GT201300167A (es)
HR (1) HRP20170595T1 (es)
HU (1) HUE033205T2 (es)
IL (1) IL226987A (es)
LT (1) LT2654780T (es)
MX (1) MX347077B (es)
MY (1) MY162489A (es)
NI (1) NI201300057A (es)
NZ (1) NZ612379A (es)
PH (1) PH12013501332B1 (es)
PL (1) PL2654780T3 (es)
PT (1) PT2654780T (es)
RS (1) RS55906B1 (es)
SG (1) SG191233A1 (es)
SI (1) SI2654780T1 (es)
SM (1) SMT201700201T1 (es)
WO (1) WO2012087746A1 (es)
ZA (1) ZA201305538B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SG191233A1 (en) * 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
SMT201900520T1 (it) 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
JP6405242B2 (ja) 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3169703B2 (en) * 2014-07-16 2023-12-13 Hinrich Abken Chimeric antigen receptor and its use
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
MX2017005467A (es) * 2014-10-27 2017-11-30 Inhibrx Lp Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
EP3259288B1 (en) 2015-02-20 2026-07-22 Innate Pharma Cd73 blockade
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
IL309260B2 (en) * 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
PE20181367A1 (es) 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CA3002588C (en) * 2015-10-23 2021-11-23 Apogenix Ag Single-chain cd137-receptor agonist proteins
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
CA3016765A1 (en) 2016-03-15 2017-09-21 Innate Pharma Anti-mica antibodies
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
US12145993B2 (en) 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
US12024560B2 (en) * 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
US20200157192A1 (en) * 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
SI3456736T1 (sl) 2017-09-19 2021-06-30 Tillotts Pharma Ag Variante protitelesa
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
WO2020198731A2 (en) * 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN114729058B (zh) * 2019-08-23 2025-08-01 希望之城 IgG抗体组合物和其制备方法
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
TW202221016A (zh) * 2020-08-07 2022-06-01 美商建南德克公司 Ｆｌｔ３配位體融合蛋白及使用方法
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
AU2023383441A1 (en) * 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN121517545A (zh) * 2024-08-13 2026-02-13 菲鹏生物股份有限公司 一种Fc突变体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
CA2331607A1 (en) 1998-05-06 1999-11-11 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2007024743A2 (en) 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP2188306B1 (en) * 2007-08-10 2016-06-29 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
US20100260751A1 (en) 2007-09-28 2010-10-14 Raju T Shantha Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2010124018A1 (en) 2009-04-21 2010-10-28 Amgen Inc. FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES
SG191233A1 (en) * 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
EP2654780A4 (en) 2015-03-18
KR101900280B1 (ko) 2018-11-08
PH12013501332A1 (en) 2013-08-28
PT2654780T (pt) 2017-04-06
JP6012624B2 (ja) 2016-10-25
AU2011349719A1 (en) 2013-07-04
AU2011349719B2 (en) 2016-09-15
MY162489A (en) 2017-06-15
RS55906B1 (sr) 2017-09-29
MX347077B (es) 2017-04-10
GT201300167A (es) 2014-09-26
SI2654780T1 (sl) 2017-06-30
ZA201305538B (en) 2015-01-28
DK2654780T3 (en) 2017-04-10
WO2012087746A1 (en) 2012-06-28
EP2654780A1 (en) 2013-10-30
EA028658B1 (ru) 2017-12-29
CO6741179A2 (es) 2013-08-30
MX2013007291A (es) 2013-09-13
SG191233A1 (en) 2013-07-31
KR20140003485A (ko) 2014-01-09
CR20130292A (es) 2013-10-03
PL2654780T3 (pl) 2017-07-31
NZ612379A (en) 2014-10-31
EP2654780B1 (en) 2017-02-01
NI201300057A (es) 2014-02-25
BR112013018317A2 (pt) 2017-03-21
PH12013501332B1 (en) 2019-01-16
US9611328B2 (en) 2017-04-04
CA2822366A1 (en) 2012-06-28
IL226987A (en) 2017-07-31
US20130011386A1 (en) 2013-01-10
CN103260640A (zh) 2013-08-21
JP2014504301A (ja) 2014-02-20
US8871204B2 (en) 2014-10-28
HUE033205T2 (en) 2017-11-28
LT2654780T (lt) 2017-03-27
HRP20170595T1 (hr) 2017-06-16
ES2623912T3 (es) 2017-07-12
EA201390958A1 (ru) 2013-11-29
CY1118923T1 (el) 2018-01-10
CN103260640B (zh) 2015-12-02
US20150139984A1 (en) 2015-05-21
SMT201700201T1 (it) 2017-05-08

Similar Documents

Publication Publication Date Title
CO6741179A2 (es) Mutantes fc de anticuerpos resistentes a proteasas activas
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
CO2017002719A2 (es) Anticuerpos anti-glucagón
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20110316A (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
PA8849001A1 (es) Anticuerpos de c-met
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
PE20150002A1 (es) Anticuerpos anti-fcrn
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
GT201700033A (es) Anticuerpos anti tigit
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
MX376058B (es) Uso de peptidos glp-1 de accion prolongada.
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
MX421100B (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
ECSP12012105A (es) Antídotos de Anticoagulantes
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
DOP2018000019A (es) Inmunoconjugados de il22
MX379312B (es) Anticuerpos especificos para fcrn.